top of page

Search

Using a cell therapy as a potential treatment for Parkinson’s with BlueRock's CEO

blonca9
Jun 28, 2023
1 min read

CEO Seth Ettenberg explains how BlueRock is using pluripotent stems cells to try to restore dopamine production in Parkinson’s patients.

Recent Posts

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page